You are currently on the new version of our website. Access the old version .
MDPIMDPI
Search all articles
PharmaceuticalsPharmaceuticals
Download PDF
  • Review
  • Open Access

25 December 2023

Photodynamic Action of Curcumin and Methylene Blue against Bacteria and SARS-CoV-2—A Review

,
and
1
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China
2
Faculty of Science and Technology, The Technological and Higher Education Institute of Hong Kong, Tsing Yi, New Territories, Hong Kong
3
School of Graduate Studies, Lingnan University, Tuen Mun, Hong Kong
*
Author to whom correspondence should be addressed.
Pharmaceuticals2024, 17(1), 34;https://doi.org/10.3390/ph17010034
This article belongs to the Special Issue Photodynamic Therapy 2023
Version Notes
Order Reprints

Abstract

Coronavirus disease 19 (COVID-19) has occurred for more than four years, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 is a strain of coronavirus, which presents high rates of morbidity around the world. Up to the present date, there are no therapeutics that can avert this form of illness, and photodynamic therapy (PDT) may be an alternative approach against SARS-CoV-2. Curcumin and methylene blue have been approved and used in clinical practices as a photosensitizer in PDT for a long time with their anti-viral properties and for disinfection through photo-inactivated SARS-CoV-2. Previously, curcumin and methylene blue with antibacterial properties have been used against Gram-positive bacteria, Staphylococcus aureus (S. aureus), and Gram-negative bacteria, Escherichia coli (E. coli), Enterococcus faecalis (E. faecalis), and Pseudomonas aeruginosa (P. aeruginosa). Methods: To conduct a literature review, nine electronic databases were researched, such as WanFang Data, PubMed, Science Direct, Scopus, Web of Science, Springer Link, SciFinder, and China National Knowledge Infrastructure (CNKI), without any regard to language constraints. In vitro and in vivo studies were included that evaluated the effect of PDT mediated via curcumin or methylene blue to combat bacteria and SARS-CoV-2. All eligible studies were analyzed and summarized in this review. Results: Curcumin and methylene blue inhibited the replication of SARS-CoV-2. The reactive oxygen species (ROS) are generated during the treatment of PDT with curcumin and methylene blue to prevent the attachment of SARS-CoV-2 on the ACE2 receptor and damage to the nucleic acids either DNA or RNA. It also modulates pro-inflammatory cytokines and attenuates the clotting effects of the host response. Conclusion: The photodynamic action of curcumin and methylene blue provides a possible approach against bacteria and SARS-CoV-2 infection because they act as non-toxic photosensitizers in PDT with an antibacterial effect, anti-viral properties, and disinfection functions.

1. Introduction

Coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the subgenus sarbecovirus (previously lineage B) of genus betacoronavirus and occupies a unique phylogenetic position that is the most lethal [1]. This virus is capable of human-to-human transmission through droplets or direct contact, causing outbreaks of pneumonia and spreading around the world quickly [2,3]. There are no therapeutics that can avert this form of illness nowadays. Western medical approaches such as booster shots and variant-specific vaccines are used for the prevention and treatment of SARS-CoV-2 [4]. However, Western medicines such as remdesivir [5] and dexamethasone [6] may cause adverse drug reactions in some patients.
Meanwhile, photodynamic therapy has been developed for COVID-19 as an antimicrobial treatment that is safe and cost-effective. Antimicrobial photodynamic therapy (aPDT) is a process utilizing a light-activating photosensitizer (PS) that is usually applied in an oxygen-rich environment [7]. The energy of photons is absorbed by the photosensitizer and subsequently transferred to surrounding molecules for generating reactive oxygen species, causing damage to the macromolecules in microbes such as proteins, lipids, and nucleic acids, resulting in structural change and death [8].
Porphyrin is a common PS used to mitigate COVID-19 by preventing infections [9]. Protoporphyrin (PpIX) was also used as a sensor to monitor the presence of SARS-CoV-2 in the tissue, blood, urine, or feces can map the evolution and severity of the disease or monitor the response of COVID-19 to treatment modalities. This fluorescence spectroscopy has been applied as a diagnostic tool for COVID-19 with a low cost and high sensitivity. PDT with PpIX was effective in combating COVID-19 in the acute phase [10]. A series of water-soluble phosphorus(V) porphyrin molecules with OH or ethoxy axial ligands and phenyl/pyridyl peripheral substituents were used as antimicrobial agents in two Gram-negative bacteria models, such as Escherichia coli (E. coli) and Acinetobacter baumannii (A. baumannii). These porphyrins with an extremely low light dose of 5 J/cm2 in MIC50 values fight against COVID-19, based on the molecular interaction between phosphorus(V) porphyrin and bacterial lipid membranes [11]. The photodynamic therapy with Tetrahydroporphyrin-tetratosylate photodynamic therapy (THPTS) was also used to prevent the infection of COVID-19 with a virus load-reducing effect only at a higher concentration of 3 µM upon near-infrared light irradiation (760 nm, 3.9 or 7.8 J/cm2), which reduced the viral load in vivo, deactivated SARS-CoV-2 [12]. Thus, tetra-p-sulphonated-phenyl porphyrin (TSPP) was able to form cationic and J-aggregates at different pH values from 1 to 4, and concentrations around 10−5 M were suitable for the application of PDT to SARS-CoV-2 viruses [13].
Besides porphyrins, curcumin and methylene blue have also been widely used in the application of PDT against different types of microbes such as viruses, bacteria, protozoa, and fungi. Curcumin and methylene blue normally have limited adverse effect profiles and less damage to the host tissue with no resistance following multiple sessions of therapy [7]. This article aimed to review and discuss (i) the background of curcumin and methylene blue, (ii) the principles of PDT, (iii) photodynamic action on diverse organisms in (a) bacteria and (b) SARS-CoV-2 from COVID-19, and its clinical studies, as well as the current approach to nanotechnology in curcumin and methylene blue for the application of PDT.

2. Principles of PDT

PDT is a minimally invasive therapeutic modality used for the management of a variety of cancers and benign diseases. It is achieved with the use of visible or near-infrared irradiation to activate a light-absorbing compound (photosensitizer, PS) for producing singlet oxygen and other reactive oxygen species (ROS) that destroy the unwanted cells in the presence of molecular oxygen [14]. There are two types of photochemical action involved in the PDT as follows:
Type I: PS is excited in a triplet state reacting with biomolecules, which transfer the hydrogen atoms to produce the free radicals and radical ions for the generation of ROS in the presence of oxygen [15,16,17,18].
Type II: PS is excited in a triplet state reacting with oxygen in its triplet ground state to produce singlet oxygen (1O2) that is highly reactive and cytotoxic [15].
Type I and Type II reactions spontaneously occur at the same time, and the equilibrium between these two processes depends on the nature of the PS, the concentration of oxygen and substrate, and the affinity of the PS with the substrate.
Basically, photochemical action from curcumin and methylene blue as a PS consists of both Type I and Type II reactions. Curcumin has shown great potential as a PS in PDT because of its ability to absorb blue light (425–500 nm) for producing ROS to target cells or tissues [19]. Methylene blue can generate a high quantum yield of 1O2 via PDT to an infected area during excitation of the red light (630–680 nm) [20].

3. Curcumin

Curcumin (Figure 1) is a natural substance extracted from Curcuma longa L. (turmeric) with the chemical structure of 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (C21H20O6), consisting of phenol groups, ketone groups, and methoxy groups for a wide variety of biological activities [21]. It has been employed for the treatment of some diseases from the time of Ayurveda (1900 Bc) [22] because of numerous pharmacological effects including its antioxidant [23], anti-inflammatory [24], antiviral [25], antibacterial [26], antifungal [27], and anticancer properties [28]. Besides therapeutic activities, it is also used in the Indian subcontinent as a gold-colored spice, either in food preservation or as a yellow dye for textiles [22].
Figure 1. Chemical structure of curcumin.
Curcumin has a broad absorption peak from 300 to 500 nm [29], and the maximum absorption peak can be divided into 408 to 430 nm in different solvent systems, such as tetrachloromethane and dimethyl sulfoxide. It is usually activated by light with a wavelength of around 425 nm to induce a strong phototoxicity at micromolar concentrations [30]. Currently, curcumin has extended its usage to antimicrobial activity for human clinical trials in a variety of conditions [31], acting as an antibacterial agent and exploiting about 100 different strains of both Gram-positive and Gram-negative pathogenic bacteria [32]. It has been used as a PS in the treatment of mouth pathogen microbes because of its photokilling and photo-biological abilities [29,33,34].
Curcumin is a suitable candidate as a PS in the application of PDT since it is a chemically pure substance with a specific uptake by the target tissue, minimal dark toxicity that is activated only upon irradiation, high photo-activity rate (quantum yield) to the production of ROS, and rapid clearance to avoid phototoxic side effects. It induces no toxic impact on healthy tissue and it should be able to be manipulated within short light intervals to ease treatment for outpatients [35].

4. Methylene Blue

Methylene blue (Figure 2) is a heterocyclic aromatic compound belonging to the phenothiazine type with the chemical structure of 7-(Dimethyl-amino)phenothiazin-3-ylidene]-dimethyla-zanium chloride (C16H18ClN3S). It consists of two benzene rings attached to one nitrogen atom and one sulfur atom and was first synthesized as a textile dyestuff by Caro in 1876 [36]. Methylene blue has been used to stain the nervous tissue [37] as an analgesic [38] and antimalarial component [39]. Nowadays, methylene blue is a well-known dye in medicine and has been applied for topical treatment during photodynamic therapy (PDT) [40].
Figure 2. Chemical structure of methylene blue.
Since methylene blue has very low tissue toxicity, it has been used in medical practice for more than a hundred years, including the treatment of ifosfamide encephalopathy, methemoglobinemia, urolithiasis, and cyanide poisoning [41]. It is non-toxic and can be administered in high doses to humans orally or intravenously [42]. Methylene blue is possible to achieve optimal light penetration into tissue because of the strong light absorption at 620 nm wavelengths; thus, this is an excellent choice for superficial treatments of the skin or oral cavity [35]. Thus, methylene blue is safe and effective for use in PDT because of its ability to generate singlet oxygen with high light absorption at 665 nm against several diseases [43].

5. Comparing the Photodynamic Action of Methylene Blue and Curcumin

Methylene blue is an FDA-approved PS [44]; curcumin is not approved as a PS and is only available in the United States as a dietary supplement [45]. However, curcumin has been used as a photosensitizer in PDT for a long time, especially in clinical studies.
Methylene blue is a hydrophilic compound with a low molecular weight and a positive charge, which easily passes through Gram-positive and Gram-negative bacterial membranes. When being irradiated by a light source of approximately 630 nm, this compound promotes irreversible oxidation of the target cells [46]. Additionally, curcumin is a hydrophobic compound. It has a high molecular weight and a neutral charge and can be irradiated by a light source of approximately 425 nm [34,47]. Compared to methylene blue, it is insoluble in water with a shorter wavelength in the application of PDT. However, curcumin is a natural product without side effects. Methylene blue is a cationic dye that may cause some health problems such as asthma and eye, or skin irritations [48,49].

6. Photodynamic Action against Bacteria

Generally, an applied therapeutic photodynamic method involves the activation of curcumin and methylene blue with blue or red lights at specific wavelengths (425–500 nm and 630–680 nm, respectively).
Growing evidence has shown that curcumin possesses antibacterial properties in aPDT treatment against Gram-positive bacteria Staphylococcus aureus (S. aureus), and Gram-negative bacteria Escherichia coli (E. coli), Enterococcus faecalis (E. faecalis), and Pseudomonas aeruginosa (P. aeruginosa). The possible mechanism of aPDT for curcumin involves producing different types of ROS, such as hydrogen peroxide, hydroxide radical, superoxide, and singlet oxygen [50]. Cytotoxic ROS react with DNA, proteins, lipids, and other components to induce cell death in organisms [51]. The singlet oxygen produced has a very small radius of action, which is less than 0.02 μm, and damage only occurs in the presence of the photosensitizer and under photoactivation. Cell death of an organism is caused by the cell wall or membrane lysis and/or the inactivation of proteins or enzymes essential for microbial metabolism [52]. The photodynamic action of methylene blue against bacteria is similar to that of curcumin. Actually, curcumin and methylene blue are very safe, and their photodynamic actions have a broad spectrum of antibacterial effects and no bacterial resistance [53,54], the PDT with curcumin and methylene blue has been used in antibacterial treatment (Table 1 and Table 2).
Table 1. The photodynamic action of curcumin against bacteria.
Table 2. The photodynamic action of methylene blue against bacteria.

7. Photodynamic Action against SARS-CoV-2

SARS-CoV-2 is a single-stranded RNA-enveloped virus that is 29,881 bp in length and encodes 9860 amino acids [80]. It breaks the plasma membrane, enters human cells, and exposes its genetic material, causing severe damage to human RNA and DNA [81]. The photodynamic action of porphyrin generates singlet oxygen (1O2), which has a diffusion distance of approximately 0.01 to 0.02 μm before quenching. Since PSs need to be closely associated with the target substrate for maximum impact, the affinity of a virus for the heme structure indicates high viral destruction. These titers are restricted to the zone of photoactivation [82].
Curcumin and methylene blue are other common PSs in the photodynamic treatment of SARS-CoV-2 (Table 3 and Table 4) that attempt to inactivate the virus. They have the ability to enter the host cell and bind to the DNA, RNA, as well as protein of the virus. When binding to DNA, RNA, or protein of the virus, cross-linking mechanics could be altered to cause damage to [83] the glycoprotein, resulting in the inhibition of viral replication [81]. Since SARS-CoV-2 requires an enveloped homotrimeric spike glycoprotein to interact with the cellular receptor ACE-2 [84] and the selective impairment of surface proteins, like spike glycoprotein, PDT can effectively inhibit the infectivity of SARS-CoV-2 [85].
Table 3. The photodynamic action of curcumin against SARS-CoV-2.
Table 4. The photodynamic action of methylene blue against SARS-CoV-2.

8. Mechanism of Photodynamic Action against SARS-CoV-2

Methylene blue has photodynamic effects used in different illnesses, including cirrhosis of the liver, hypoxemia, and severe hepatopulmonary syndrome [92]. It reduces the oxidized ferric form of hemoglobin (Fe3+), which permanently binds oxygen to the ferrous (Fe2+) form. This improves hemoglobin’s ability to bind oxygen and, as a result, oxygen transport to tissues, which is beneficial for COVID-19 patients [93]. Silent hypoxemia is the term for the low oxygen levels that COVID-19 patients frequently exhibit. These levels are usually incompatible with a life without dyspnea [94].
Curcumin can improve COVID-19 patients’ prognoses by drastically reducing the length of common symptoms, hospital stays, and mortality [95]. It inhibits the ACE2 receptor and the SARS-CoV-2 S protein, as well as SARS-CoV-2 proteases such as papain-like protease and main protease [96,97]. Additionally, curcumin can dramatically lower inflammatory cytokine levels and stimulate anti-inflammatory pathways, which raises anti-inflammatory cytokine levels and partially restores the pro- and anti-inflammatory chemical balance in COVID-19 patients. This may help to control the cytokine storm associated with COVID-19 [96].

9. Clinical Study for COVID-19

Curcumin is widely found in food and it is a safe drug with broad prospects for clinical application [98]. The use of nanocurcumin is a successful practice, and effectively increases O2 saturation and reduces the severity of symptoms in COVID-19 patients [99]. The minor side effects of an intake of curcumin formulations include colds, irritation, indigestibility, and nausea, which in a few cases might be attributed to adjuvants and emulsifiers [100]. However, most of these studies are single-center studies with small populations and different oral doses of nanocurcumin. It is better to have more long-term, multi-center, and large-sample studies [96].
Methylene blue can also be used for COVID-19 treatment [101]. However, administration of methylene blue with meticulous consideration of the dosage is necessary to prevent any untoward effects, since methylene blue is a monoamine oxidase (MAO) inhibitor and can interact with antidepressants to cause severe toxicity of serotonin [102]. It has also been found to interact with dapsone to form hydroxylamine, which oxidizes hemoglobin and may cause hemolysis [103]. In patients with G6PD deficiency, this can be detrimental and may cause severe hemolysis [104]. Thus, this needs to be studied further to find the optimal dosage for clinical study.

10. Discussion

PDT, with high cure rates, minimal toxicity in healthy tissues, specific targeting and selectivity, and a low amount of side effects, shows potential for use as an adjuvant therapy when combined well with all other tumor interventions such as chemotherapy, surgery, radiotherapy, immunotherapy, or treatment of cancer [105]. However, curcumin as a PS used in the clinical application of PDT has some limitations, such as poor solubility, stability, and photostability in aqueous solutions, as well as rapid metabolism and systemic elimination [106]. Methylene blue is more soluble in water but its clinical use has been limited by the rapid enzymatic reduction in the biological environment [107].
These problems of curcumin and methylene blue could be overcome with the help of nanotechnology, which produces nanoscale curcumin or methylene blue; its physical specifications, chemical properties, and biological characteristics enable it to have great bioavailability, solubility, transport, and effectiveness [108]. Nanotechnology improves the characteristics of curcumin and endows it with the ability to target an infected area, as well as inhibit viral replications that prevent the TMPRSS2 from interacting with disintegrin metallopeptidase domain 17 (ADAM17) to give a high level of ACE2 expression, causing lung inflammation and pulmonary oedema [109].
The nanocurcumin could inhibit natural killer cells and T helper 17 cells, as well as reduce the release of inflammatory factors such as IL-1β, IL-6, and TNF-α. Since nanocurcumin may effectively increase O2 saturation and reduce the severity of symptoms in COVID-19 patients, the formulations might be used as a supplement to accelerate the recovery of patients, improve the symptoms, and shorten the recovery period of COVID-19 patients [99].
Additionally, methylene blue-embedded nano or microparticles could effectively deliver photo-responsive molecules to tissues and cells for translocating them into cellular compartments, thereby producing significant amounts of ROS in the target tissues. Methylene blue would maximize the therapeutic efficacy of PDT while reducing immunogenicity and side effects [110].
The solubility of curcumin and methylene blue could also be improved via the formation of nanogels, ranging from 10 to 100 nm [111]. These nanogels are composed of hydrogel and synthesized through either the physical or chemical cross-linking of polymers. The cross-linked structure provides a sustainable storage and release rate [112]. They are developed as carriers for curcumin and methylene blue delivery because the nanogels could absorb biologically active molecules spontaneously via the formation of salt bonds, hydrogen bonds, or hydrophobic interactions to enhance their bioavailability, such as by enhancing their solubility and stability.
Thus, PDT with nano-scale curcumin or methylene blue as a potential therapy against SARS-CoV-2 is still being investigated; but much more research work needs to be carried out, especially concerning safety assessments for human clinical trials.

11. Conclusions

The above information demonstrates that curcumin and methylene blue are two promising photosensitizers for PDT with an antibacterial effect, anti-viral properties, and disinfection function. It presents a possible against bacteria and SARS-CoV-2 infection. The photodynamic action of curcumin and methylene blue can be enhanced with the help of nanotechnology in future developments.

Author Contributions

Conceptualization, S.K.L. and C.X.; writing—original draft preparation, S.K.L. and C.X.; writing—review and editing, S.K.L. and C.X.; supervision, A.W.N.L. and C.X.; funding acquisition, C.X. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Plan for Enhancing Scientific Research in Guangzhou Medical University (02-410-2302366XM).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020, 382, 1708–1720. [Google Scholar] [CrossRef] [PubMed]
  2. Zhao, S.; Lin, Q.; Ran, J.; Musa, S.S.; Yang, G.; Wang, W.; Lou, Y.; Gao, D.; Yang, L.; He, D.; et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. Int. J. Infect. Dis. 2020, 92, 214–217. [Google Scholar] [CrossRef] [PubMed]
  3. Law, S.; Leung, A.W.; Xu, C. Severe acute respiratory syndrome (SARS) and coronavirus disease-2019 (COVID-19): From causes to preventions in Hong Kong. Int. J. Infect. Dis. 2020, 94, 156–163. [Google Scholar] [CrossRef] [PubMed]
  4. Chirico, F.; Teixeira da Silva, J.A.; Tsigaris, P.; Sharun, K. Safety & effectiveness of COVID-19 vaccines: A narrative review. Indian. J. Med. Res. 2022, 155, 91–104. [Google Scholar]
  5. Spinner, C.D.; Gottlieb, R.L.; Criner, G.J.; Arribas López, J.R.; Cattelan, A.M.; Soriano Viladomiu, A.; Ogbuagu, O.; Malhotra, P.; Mullane, K.M.; Castagna, A.; et al. GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA 2020, 324, 1048–1057. [Google Scholar] [CrossRef] [PubMed]
  6. Horby, P.; Lim, W.S.; Emberson, J.R.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; et al. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2021, 384, 693–704. [Google Scholar]
  7. Ghorbani, J.; Rahban, D.; Aghamiri, S.; Teymouri, A.; Bahador, A. Photosensitizers in antibacterial photodynamic therapy: An overview. Laser Ther. 2018, 27, 293–302. [Google Scholar] [CrossRef]
  8. Huang, L.; Xuan, Y.; Koide, Y.; Zhiyentayev, T.; Tanaka, M.; Hamblin, M.R. Type I and Type II mechanisms of antimicrobial photodynamic therapy: An in vitro study on gram-negative and gram-positive bacteria. Lasers Surg. Med. 2012, 44, 490–499. [Google Scholar] [CrossRef]
  9. Almeida, A.; Faustino, M.A.F.; Neves, M.G.P.M.S. Antimicrobial Photodynamic Therapy in the Control of COVID-19. Antibiotics 2020, 9, 320. [Google Scholar] [CrossRef]
  10. Courrol, L.C.; de Oliveira Silva, F.R.; Masilamani, V. SARS-CoV-2, hemoglobin and protoporphyrin IX: Interactions and perspectives. Photodiagnosis Photodyn. Ther. 2021, 34, 102324. [Google Scholar] [CrossRef]
  11. Batishchev, O.V.; Kalutskii, M.A.; Varlamova, E.A.; Konstantinova, A.N.; Makrinsky, K.I.; Ermakov, Y.A.; Meshkov, I.N.; Sokolov, V.S.; Gorbunova, Y.G. Antimicrobial activity of photosensitizers: Arrangement in bacterial membrane matters. Front. Mol. Biosci. 2023, 15, 1192794. [Google Scholar] [CrossRef] [PubMed]
  12. Ziganshyna, S.; Szczepankiewicz, G.; Kuehnert, M.; Schulze, A.; Liebert, U.G.; Pietsch, C.; Eulenburg, V.; Werdehausen, R. Photodynamic Inactivation of SARS-CoV-2 Infectivity and Antiviral Treatment Effects In Vitro. Viruses 2022, 14, 1301. [Google Scholar] [CrossRef] [PubMed]
  13. Ion, R.M. Revisiting Tetra-p-Sulphonated Porphyrin as Antimicrobial Photodynamic Therapy Agent. Coatings 2021, 11, 393. [Google Scholar] [CrossRef]
  14. Benov, L. Photodynamic therapy: Current status and future directions. Med. Princ. Pract. 2015, 24 (Suppl. S1), 14–28. [Google Scholar] [CrossRef] [PubMed]
  15. Kharkwal, G.B.; Sharma, S.K.; Huang, Y.Y.; Dai, T.; Hamblin, M.R. Photodynamic therapy for infections: Clinical applications. Lasers Surg. Med. 2011, 43, 755–767. [Google Scholar] [CrossRef] [PubMed]
  16. Ribeiro, M.S.; da Silva, D.d.F.T.; Cristina Nunez, S.; Zezell, M.D. Laser em baixa intensidade. In Técnicas e Procedimentos Terapêuticos; Quintessense Editora: São Paulo, SP, Brazil, 2004; pp. 945–953. [Google Scholar]
  17. Dolmans, D.E.J.G.J.; Fukumura, D.; Jain, R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer. 2003, 3, 380–387. [Google Scholar] [CrossRef] [PubMed]
  18. Machado, A.E.d.H. Terapia fotodinâmica: Princípios, potencial de aplicação e perspectivas. Quim. Nova 2000, 23, 237–243. [Google Scholar] [CrossRef]
  19. Calixto, G.M.; Bernegossi, J.; de Freitas, L.M.; Fontana, C.R.; Chorilli, M. Nanotechnology-Based Drug Delivery Systems for Photodynamic Therapy of Cancer: A Review. Molecules 2016, 21, 342. [Google Scholar] [CrossRef]
  20. Boltes Cecatto, R.; Siqueira de Magalhães, L.; Fernanda Setúbal Destro Rodrigues, M.; Pavani, C.; Lino-Dos-Santos-Franco, A.; Teixeira Gomes, M.; Fátima Teixeira Silva, D. Methylene blue mediated antimicrobial photodynamic therapy in clinical human studies: The state of the art. Photodiagnosis Photodyn. Ther. 2020, 31, 101828. [Google Scholar] [CrossRef]
  21. Law, S.; Lo, C.; Han, J.; Yang, F.; Leung, A.W.; Xu, C. Design, Synthesis and Characterization of Novel Curcumin Derivatives. Nat. Prod. Chem. Res. 2020, 8, 367. [Google Scholar]
  22. Aggarwal, B.B.; Sundaram, C.; Malani, N.; Ichikawa, H. Curcumin: The Indian solid gold. Adv. Exp. Med. Biol. 2007, 595, 1–75. [Google Scholar] [PubMed]
  23. Jakubczyk, K.; Drużga, A.; Katarzyna, J.; Skonieczna-Żydecka, K. Antioxidant Potential of Curcumin-A Meta-Analysis of Randomized Clinical Trials. Antioxidants 2020, 9, 1092. [Google Scholar] [CrossRef] [PubMed]
  24. Menon, V.P.; Sudheer, A.R. Antioxidant and anti-inflammatory properties of curcumin. Adv. Exp. Med. Biol. 2007, 595, 105–125. [Google Scholar] [PubMed]
  25. Jennings, M.R.; Parks, R.J. Curcumin as an Antiviral Agent. Viruses 2020, 12, 1242. [Google Scholar] [CrossRef] [PubMed]
  26. Tajbakhsh, S.; Mohammadi, K.; Deilami, I.; Keivan, Z.; Fouladvand, M.; Ramedani, E.; Asayesh, G. Antibacterial activity of indium curcumin and indium diacetylcurcumin. Afr. J. Biotechnol. 2008, 7, 3832–3835. [Google Scholar]
  27. Martins, C.V.; da Silva, D.L.; Neres, A.T.; Magalhães, T.F.; Watanabe, G.A.; Modolo, L.V.; Sabino, A.A.; de Fátima, A.; de Resende, M.A. Curcumin as a promising antifungal of clinical interest. J. Antimicrob. Chemother. 2009, 63, 337–339. [Google Scholar] [CrossRef] [PubMed]
  28. Aggarwal, B.B.; Kumar, A.; Bharti, A.C. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer. Res. 2003, 23, 363–398. [Google Scholar]
  29. Leite, D.P.; Paolillo, F.R.; Parmesano, T.N.; Fontana, C.R.; Bagnato, V.S. Effects of photodynamic therapy with blue light and curcumin as mouth rinse for oral disinfection: A randomized controlled trial. Photomed. Laser Surg. 2014, 32, 627–632. [Google Scholar] [CrossRef]
  30. Sreedhar, A.; Sarkar, I.; Rajan, P.; Pai, J.; Malagi, S.; Kamath, V.; Barmappa, R. Comparative evaluation of the efficacy of curcumin gel with and without photo activation as an adjunct to scaling and root planing in the treatment of chronic periodontitis: A split mouth clinical and microbiological study. J. Nat. Sci. Biol. Med. 2015, 6 (Suppl. S1), S102–S109. [Google Scholar] [CrossRef]
  31. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin: From ancient medicine to current clinical trials. Cell Mol. Life Sci. 2008, 65, 1631–1652. [Google Scholar] [CrossRef]
  32. Adamczak, A.; Ożarowski, M.; Karpiński, T.M. Curcumin, a Natural Antimicrobial Agent with Strain-Specific Activity. Pharmaceuticals 2020, 13, 153. [Google Scholar] [CrossRef]
  33. Dahl, T.A.; McGowan, W.M.; Shand, M.A.; Srinivasan, V.S. Photokilling of bacteria by the natural dye curcumin. Arch. Microbiol. 1989, 151, 183–185. [Google Scholar] [CrossRef]
  34. Kah, G.; Chandran, R.; Abrahamse, H. Curcumin a Natural Phenol and Its Therapeutic Role in Cancer and Photodynamic Therapy: A Review. Pharmaceutics. 2023, 15, 639. [Google Scholar] [CrossRef]
  35. Allison, R.R.; Downie, G.H.; Cuenca, R.; Hu, X.H.; Childs, C.J.; Sibata, C.H. Photosensitizers in clinical PDT. Photodiagnosis Photodyn. Ther. 2004, 1, 27–42. [Google Scholar] [CrossRef]
  36. Friedlaender, P. Fortschritte der Theerfarbenfabrikation und Verwandter Industriezweige; Springer: Berlin, Germany, 1877. [Google Scholar]
  37. Ehrlich, P. Ueber die Methylenblaureaction der lebenden Nervensubstanz. Dtsch. Med. Wochenschr. 1886, 12, 49–52. [Google Scholar] [CrossRef][Green Version]
  38. Ehrlich, P.; Leppmann, A. Ueber schmerzstillende wirkung des methylenblau. Dtsch. Med. Wochenschr. 1890, 16, 493–494. [Google Scholar] [CrossRef][Green Version]
  39. Kaufmann, P. Über die Wirkung von Methylenblau bei Malaria. Dtsch. Med. Wochenschr. 1919, 45, 1365. [Google Scholar] [CrossRef]
  40. Orth, K.; Beck, G.; Genze, F.; Rück, A. Methylene blue mediated photodynamic therapy in experimental colorectal tumors in mice. J. Photochem. Photobiol. B 2000, 57, 186–192. [Google Scholar] [CrossRef]
  41. Kupfer, A.; Aeschilmann, C.; Wermuth, B.; Cerny, T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994, 343, 763–764. [Google Scholar] [CrossRef]
  42. McEvoy, G.K. AHFS Drug Information. Oncology Issues 2017, 9, 12–13. [Google Scholar] [CrossRef]
  43. Bisland, S.K.; Chien, C.; Wilson, B.C.; Burch, S. Pre-clinical in vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis. Photochem. Photobiol. Sci. 2006, 5, 31–38. [Google Scholar] [CrossRef] [PubMed]
  44. Hepburn, J.; Williams-Lockhart, S.; Bensadoun, R.J.; Hanna, R. A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up. Antioxidants 2022, 11, 2211. [Google Scholar] [CrossRef] [PubMed]
  45. PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Curcumin (Curcuma, Turmeric) and Cancer (PDQ®): Health Professional Version. 1 September 2023. In PDQ Cancer Information Summaries; National Cancer Institute (US): Bethesda, MD, USA, 2002. [Google Scholar]
  46. Ucuncu, M.; Mills, B.; Duncan, S.; Staderini, M.; Dhaliwal, K.; Bradley, M. Polymyxin-based photosensitizer for the potent and selective killing of Gram-negative bacteria. Chem. Commun. 2020, 56, 3757–3760. [Google Scholar] [CrossRef] [PubMed]
  47. Sivieri-Araujo, G.; Strazzi-Sahyon, H.B.; Jacomassi, D.P.; Dos Santos, P.H.; Cintra, L.T.A.; Kurachi, C.; Bagnato, V.S. Effects of methylene blue and curcumin photosensitizers on the color stability of endodontically treated intraradicular dentin. Photodiagnosis Photodyn. Ther. 2022, 37, 102650. [Google Scholar] [CrossRef] [PubMed]
  48. Mohammadpour, A.; Karami, N.; Zabihi, R.; Fazeliyan, E.; Abbasi, A.; Karimi, S.; Barbosa de Farias, M.; Adeodato Vieira, M.G.; Shahsavani, E.; Mousavi Khaneghah, A. Green synthesis, characterization, and application of Fe3O4 nanoparticles for methylene blue removal: RSM optimization, kinetic, isothermal studies, and molecular simulation. Environ. Res. 2023, 225, 115507. [Google Scholar] [CrossRef] [PubMed]
  49. Pivetta, T.P.; Vieira, T.; Silva, J.C.; Ribeiro, P.A.; Raposo, M. Phototoxic Potential of Different DNA Intercalators for Skin Cancer Therapy: In Vitro Screening. Int. J. Mol. Sci. 2023, 24, 5602. [Google Scholar] [CrossRef] [PubMed]
  50. Kashef, N.; Hamblin, M.R. Can microbial cells develop resistance to oxidative stress in antimicrobial photodynamic inactivation? Drug Resist. Updates 2017, 31, 31–42. [Google Scholar] [CrossRef]
  51. Hu, F.; Xu, S.; Liu, B. Photosensitizers with Aggregation-Induced Emission: Materials and Biomedical Applications. Adv. Mater. 2018, 30, e1801350. [Google Scholar] [CrossRef]
  52. Harris, F.; Chatfield, L.; Phoenix, D. Phenothiazinium Based Photosensitisers—Photodynamic Agents with a Multiplicity of Cellular Targets and Clinical Applications. Curr. Drug Targets, 2005; Epub ahead of print. [Google Scholar]
  53. Bartolomeu, M.; Rocha, S.; Cunha, Â.; Neves, M.G.P.M.S.; Faustino, M.A.F.; Almeida, A. Effect of Photodynamic Therapy on the Virulence Factors of Staphylococcus aureus. Front. Microbiol. 2016, 7, 267. [Google Scholar] [CrossRef]
  54. Wang, C.; Chen, P.; Qiao, Y.; Kang, Y.; Yan, C.; Yu, Z.; Wang, J.; He, X.; Wu, H. pH responsive superporogen combined with PDT based on poly Ce6 ionic liquid grafted on SiO2 for combating MRSA biofilm infection. Theranostics 2020, 10, 4795–4808. [Google Scholar] [CrossRef]
  55. Ribeiro, I.P.; Pinto, J.G.; Souza, B.M.N.; Miñán, A.G.; Ferreira-Strixino, J. Antimicrobial photodynamic therapy with curcumin on methicillin-resistant Staphyloccocus aureus biofilm. Photodiagnosis Photodyn. Ther. 2022, 37, 102729. [Google Scholar] [CrossRef]
  56. Muniz, I.P.R.; Galantini, M.P.L.; Ribeiro, I.S.; Gonçalves, C.V.; Dos Santos, D.P.; Moura, T.C.; Silva, E.S.; Silva, N.R.; Cipriano, B.P.; Correia, T.M.L.; et al. Antimicrobial photodynamic therapy (aPDT) with curcumin controls intradermal infection by Staphyloccocus aureus in mice with type 1 diabetes mellitus: A pilot study. J. Photochem. Photobiol. B 2021, 224, 112325. [Google Scholar] [CrossRef]
  57. Jiang, Y.; Leung, A.W.; Hua, H.; Rao, X.; Xu, C. Photodynamic Action of LED-Activated Curcumin against Staphyloccocus aureus Involving Intracellular ROS Increase and Membrane Damage. Int. J. Photoenergy. 2014, 2014, 637601. [Google Scholar] [CrossRef]
  58. Freitas, M.A.A.; Pereira, A.H.C.; Pinto, J.G.; Casas, A.; Ferreira-Strixino, J. Bacterial viability after antimicrobial photodynamic therapy with curcumin on multiresistant Staphylococcus aureus. Future Microbiol. 2019, 14, 42. [Google Scholar] [CrossRef]
  59. Astuti, S.D.; Mahmud, A.F.; Pudjiyanto; Mukhammad, Y.; Fitriyah, N. Antimicrobial photodynamic of blue LED for activation of curcumin extract (curcuma longa) on Staphyloccocus aureus bacteria, an in vitro study. J. Phys. Conf. Ser. 2018, 1120, 012073. [Google Scholar] [CrossRef]
  60. Almeida, P.P.; Pereira, Í.S.; Rodrigues, K.B.; Leal, L.S.; Marques, A.S.; Rosa, L.P.; da Silva, F.C.; da Silva, R.A.A. Photodynamic therapy controls of Staphyloccocus aureus intradermal infection in mice. Lasers Med. Sci. 2017, 32, 1337–1342. [Google Scholar] [CrossRef]
  61. Haukvik, T.; Bruzell, E.; Kristensen, S.; Tønnesen, H.H. Photokilling of bacteria by curcumin in different aqueous preparations. Studies on curcumin and curcuminoids XXXVII. Pharmazie 2009, 64, 666–673. [Google Scholar]
  62. Mushtaq, S.; Yasin, T.; Saleem, M.; Dai, T.; Yameen, M.A. Potentiation of Antimicrobial Photodynamic Therapy by Curcumin-loaded Graphene Quantum Dots. Photochem. Photobiol. 2022, 98, 202–210. [Google Scholar] [CrossRef]
  63. Wikene, K.O.; Hegge, A.B.; Bruzell, E.; Tønnesen, H.H. Formulation and characterization of lyophilized curcumin solid dispersions for antimicrobial photodynamic therapy (aPDT): Studies on curcumin and curcuminoids LII. Drug Dev. Ind. Pharm. 2015, 41, 969–977. [Google Scholar] [CrossRef]
  64. Moradi, M.; Fazlyab, M.; Pourhajibagher, M.; Chiniforush, N. Antimicrobial action of photodynamic therapy on Enterococcus faecalis biofilm using curing light, curcumin and riboflavin. Aust. Endod. J. 2022, 48, 274–282. [Google Scholar] [CrossRef]
  65. Cusicanqui Méndez, D.A.; Cardenas Cuéllar, M.R.; Feliz Pedrinha, V.; Velásquez Espedilla, E.G.; Bombarda de Andrade, F.; Rodrigues, P.A.; Cruvinel, T. Effects of curcumin-mediated antimicrobial photodynamic therapy associated to different chelators against Enterococcus faecalis biofilms. Photodiagnosis Photodyn. Ther. 2021, 35, 102464. [Google Scholar] [CrossRef]
  66. Abdulrahman, H.; Misba, L.; Ahmad, S.; Khan, A.U. Curcumin induced photodynamic therapy mediated suppression of quorum sensing pathway of Pseudomonas aeruginosa: An approach to inhibit biofilm in vitro. Photodiagnosis Photodyn. Ther. 2020, 30, 101645. [Google Scholar] [CrossRef] [PubMed]
  67. Zhou, F.; Lin, S.; Zhang, J.; Kong, Z.; Tan, B.K.; Hamzah, S.S.; Hu, J. Enhancement of photodynamic bactericidal activity of curcumin against Pseudomonas aeruginosa using polymyxin B. Photodiagnosis Photodyn. Ther. 2022, 37, 102677. [Google Scholar] [CrossRef] [PubMed]
  68. Geralde, M.C.; Corrêa, T.Q.; Vollet-Filho, J.D.; Kurachi, C.; Bagnato, V.S.; Pratavieira, S.; de Souza, C.W.O. Evaluation of curcumin incubation time in Staphyloccocus aureus and Pseudomonas aeruginosa Photodynamic Inactivation. In 2021 SBFoton International Optics and Photonics Conference (SBFoton IOPC); IEEE: Toulouse, France, 2021; pp. 1–4. [Google Scholar]
  69. Cieplik, F.; Deng, D.; Crielaard, W.; Buchalla, W.; Hellwig, E.; Al-Ahmad, A.; Maisch, T. Antimicrobial photodynamic therapy: What we know and what we don’t. Crit. Rev. Microbiol. 2018, 44, 571–589. [Google Scholar] [CrossRef] [PubMed]
  70. Pérez-Laguna, V.; García-Luque, I.; Ballesta, S.; Pérez-Artiaga, L.; Lampaya-Pérez, V.; Rezusta, A.; Gilaberte, Y. Photodynamic therapy using methylene blue, combined or not with gentamicin, against Staphyloccocus aureus and Pseudomonas aeruginosa. Photodiagnosis Photodyn. Ther. 2020, 31, 101810. [Google Scholar] [CrossRef] [PubMed]
  71. Zolfaghari, P.S.; Packer, S.; Singer, M.; Nair, S.P.; Bennett, J.; Street, C.; Wilson, M. In vivo killing of Staphyloccocus aureus using a light-activated antimicrobial agent. BMC Microbiol. 2009, 9, 27. [Google Scholar] [CrossRef]
  72. Virych, P.; Nadtoka, O.; Virych, P.; Kutsevol, N. Antimicrobial photoinactivation with methylene blue of Staphylococcus aureus. Mol. Cryst. Liq. 2021, 716, 123–128. [Google Scholar] [CrossRef]
  73. MiyabeI, M.; JunqueiraI, J.C.; Pereira da CostaI, A.C.B.; JorgeI, A.O.C.; RibeiroII, M.S.; FeistII, I.S. Effect of photodynamic therapy on clinical isolates of Staphylococcus spp. Braz. Oral Res. 2011, 25, 230–234. [Google Scholar] [CrossRef]
  74. de Oliveira, B.P.; dos Santos Accioly Lins, C.C.; Diniz, F.A.; Melo, L.L.; de Castro, C.M.M.B. In Vitro antimicrobial photoinactivation with methylene blue in different microorganisms. Braz. J. Oral. Sci. 2014, 13, 53–57. [Google Scholar] [CrossRef][Green Version]
  75. Rosa, L.P.; Silva, F.C.; Nader, S.A.; Meira, G.A.; Viana, M.S. Effectiveness of antimicrobial photodynamic therapy using a 660 nm laser and methyline blue dye for inactivating Staphyloccocus aureus biofilms in compact and cancellous bones: An in vitro study. Photodiagnosis Photodyn. Ther. 2015, 12, 276–281. [Google Scholar] [CrossRef]
  76. Hampden-Martin, A.; Fothergill, J.; El Mohtadi, M.; Chambers, L.; Slate, A.J.; Whitehead, K.A.; Shokrollahi, K. Photodynamic antimicrobial chemotherapy coupled with the use of the photosensitizers methylene blue and temoporfin as a potential novel treatment for Staphylococcus aureus in burn infections. Access Microbiol. 2021, 3, 000273. [Google Scholar] [CrossRef] [PubMed]
  77. Pereira, A.H.C.; Pinto, J.G.; Freitas, M.A.A.; Fontana, L.C.; Pacheco Soares, C.; Ferreira-Strixino, J. Methylene blue internalization and photodynamic action against clinical and ATCC Pseudomonas aeruginosa and Staphyloccocus aureus strains. Photodiagnosis Photodyn. Ther. 2018, 22, 43–50. [Google Scholar] [CrossRef] [PubMed]
  78. Silva, E.J.; Coutinho-Filho, W.P.; Andrade, A.O.; Herrera, D.R.; Coutinho-Filho, T.S.; Krebs, R.L. Evaluation of photodynamic therapy using a diode laser and different photosensitizers against Enterococcus faecalis. Acta Odontol. Latinoam. 2014, 27, 63–65. [Google Scholar] [PubMed]
  79. Mozayeni, M.A.; Vatandoost, F.; Asnaashari, M.; Shokri, M.; Azari-Marhabi, S.; Asnaashari, N. Comparing the Efficacy of Toluidine Blue, Methylene Blue and Curcumin in Photodynamic Therapy Against Enterococcus faecalis. J. Lasers Med. Sci. 2020, 11 (Suppl. S1), S49–S54. [Google Scholar] [CrossRef] [PubMed]
  80. Chen, L.; Liu, W.; Zhang, Q.; Xu, K.; Ye, G.; Wu, W.; Sun, Z.; Liu, F.; Wu, K.; Zhong, B.; et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg. Microbes. Infect. 2020, 9, 313–319. [Google Scholar] [CrossRef] [PubMed]
  81. Wiehe, A.; O’Brien, J.M.; Senge, M.O. Trends and targets in antiviral phototherapy. Photochem. Photobiol. Sci. 2019, 18, 2565–2612. [Google Scholar] [CrossRef] [PubMed]
  82. Moan, J.; Berg, K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem. Photobiol. 1991, 53, 549–553. [Google Scholar] [CrossRef]
  83. Lenard, J.; Rabson, A.; Vanderoef, R. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: Inhibition of fusion and syncytia formation. Proc. Natl. Acad. Sci. USA 1993, 90, 158–162. [Google Scholar] [CrossRef]
  84. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280. [Google Scholar] [CrossRef]
  85. Sharshov, K.; Solomatina, M.; Kurskaya, O.; Kovalenko, I.; Kholina, E.; Fedorov, V.; Meerovich, G.; Rubin, A.; Strakhovskaya, M. The Photosensitizer Octakis(Cholinyl)Zinc Phthalocyanine with Ability to Bind to a Model Spike Protein Leads to a Loss of SARS-CoV-2 Infectivity In Vitro When Exposed to Far-Red LED. Viruses 2021, 13, 643. [Google Scholar] [CrossRef]
  86. Zupin, L.; Fontana, F.; Clemente, L.; Borelli, V.; Ricci, G.; Ruscio, M.; Crovella, S. Optimization of Anti-SARS-CoV-2 Treatments Based on Curcumin, Used Alone or Employed as a Photosensitizer. Viruses 2022, 14, 2132. [Google Scholar] [CrossRef] [PubMed]
  87. Pourhajibagher, M.; Azimi, M.; Haddadi-Asl, V.; Ahmadi, H.; Gholamzad, M.; Ghorbanpour, S.; Bahador, A. Robust antimicrobial photodynamic therapy with curcumin-poly (lactic-co-glycolic acid) nanoparticles against COVID-19: A preliminary in vitro study in Vero cell line as a model. Photodiagnosis Photodyn. Ther. 2021, 34, 102286. [Google Scholar] [CrossRef] [PubMed]
  88. Preis, E.; Baghdan, E.; Agel, M.R.; Anders, T.; Pourasghar, M.; Schneider, M.; Bakowsky, U. Spray dried curcumin loaded nanoparticles for antimicrobial photodynamic therapy. Eur. J. Pharm. Biopharm. 2019, 142, 531–539. [Google Scholar] [CrossRef] [PubMed]
  89. Law, S.K.; Lo, C.M.; Han, J.; Leung, A.W.; Xu, C.S. Could Curcumin hydrogel for photodynamic therapy fight against SARS-CoV-2? Biointerface Res. Appl. Chem. 2023, 13, 145. [Google Scholar]
  90. Lobo, C.S.; Rodrigues-Santos, P.; Pereira, D. Photodynamic disinfection of SARS-CoV-2 clinical samples using a methylene blue formulation. Photochem. Photobiol. Sci. 2022, 21, 1101–1109. [Google Scholar] [CrossRef] [PubMed]
  91. Arentz, J.; von der Heide, H.J. Evaluation of methylene blue based photodynamic inactivation (PDI) against intracellular B-CoV and SARS-CoV2 viruses under different light sources in vitro as a basis for new local treatment strategies in the early phase of a Covid19 infection. Photodiagnosis Photodyn. Ther. 2022, 37, 102642. [Google Scholar] [CrossRef] [PubMed]
  92. Schirmer, R.H.; Adler, H.; Pickhardt, M.; Mandelkow, E. Lest we forget you--methylene blue. Neurobiol. Aging. 2011, 32, 2325–2416. [Google Scholar] [CrossRef]
  93. Bistas, E.; Sanghavi, D. Methylene Blue; StatPearls: Treasure Island, FL, USA, 2022. [Google Scholar]
  94. Tobin, M.J.; Laghi, F.; Jubran, A. Why COVID-19 silent hypoxemia is baffling to physicians. Am. J. Respir. Crit. Care Med. 2020, 202, 356–360. [Google Scholar] [CrossRef]
  95. Vahedian-Azimi, A.; Abbasifard, M.; Rahimi-Bashar, F.; Guest, P.C.; Majeed, M.; Mohammadi, A.; Banach, M.; Jamialahmadi, T.; Sahebkar, A. Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials. Nutrients 2022, 14, 256. [Google Scholar] [CrossRef]
  96. Liu, K.; Zhu, Y.; Cao, X.; Liu, Y.; Ying, R.; Huang, Q.; Gao, P.; Zhang, C. Curcumin as an antiviral agent and immune-inflammatory modulator in COVID-19: A scientometric analysis. Heliyon 2023, 9, e21648. [Google Scholar] [CrossRef]
  97. Golpour-Hamedani, S.; Pourmasoumi, M.; Askari, G.; Bagherniya, M.; Majeed, M.; Guest, P.C.; Sahebkar, A. Antiviral Mechanisms of Curcumin and Its Derivatives in Prevention and Treatment of COVID-19: A Review. Adv. Exp. Med. Biol. 2023, 1412, 397–411. [Google Scholar] [PubMed]
  98. Imran, M.; Thabet, H.K.; Alaqel, S.I.; Alzahrani, A.R.; Abida, A.; Alshammari, M.K. The therapeutic and prophylactic potential of quercetin against COVID-19: An outlook on the clinical studies, inventive compositions, and patent literature. Antioxidants 2022, 11, 876. [Google Scholar] [CrossRef] [PubMed]
  99. Valizadeh, H.; Abdolmohammadi-Vahid, S.; Danshina, S.; Ziya Gencer, M.; Ammari, A.; Sadeghi, A. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int. Immunopharm. 2020, 89 Pt B, 107088. [Google Scholar] [CrossRef]
  100. Hegde, M.; Girisa, S.; BharathwajChetty, B.; Vishwa, R.; Kunnumakkara, A.B. Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far? ACS Omega. 2023, 8, 10713–10746. [Google Scholar] [CrossRef] [PubMed]
  101. Ghahestani, S.M.; Shahab, E.; Karimi, S.; Madani, M.H. Methylene blue may have a role in the treatment of COVID-19. Med. Hypotheses. 2020, 144, 110163. [Google Scholar] [CrossRef] [PubMed]
  102. Top, W.M.; Gillman, P.K.; de Langen, C.J.; Kooy, A. Fatal methylene blue associated serotonin toxicity. Neth. J. Med. 2014, 72, 179–181. [Google Scholar] [PubMed]
  103. Clifton, J.; Leikin, J.B. Methylene blue. Am. J. Ther. 2003, 10, 289–291. [Google Scholar] [CrossRef] [PubMed]
  104. Ginimuge, P.R.; Jyothi, S.D. Methylene blue: Revisited. J. Anaesthesiol. Clin. Pharmacol. 2010, 26, 517–520. [Google Scholar] [CrossRef]
  105. Agostinis, P.; Berg, K.; Cengel, K.A.; Foster, T.H.; Girotti, A.W.; Gollnick, S.O.; Hahn, S.M.; Hamblin, R.; Juzeniene, A.; Kessel, D.; et al. Photodynamic therapy of cancer: An update. CA Cancer J. Clin. 2011, 61, 250–281. [Google Scholar] [CrossRef]
  106. Cozzolino, M.; Delcanale, P.; Montali, C.; Tognolini, M.; Giorgio, C.; Corrado, M.; Cavanna, L.; Bianchini, P.; Diaspro, A.; Abbruzzetti, S.; et al. Enhanced photosensitizing properties of protein bound curcumin. Life Sci. 2019, 233, 116710. [Google Scholar] [CrossRef]
  107. Seong, D.Y.; Kim, Y.J. Enhanced photodynamic therapy efficacy of methylene blue-loaded calcium phosphate nanoparticles. J. Photochem. Photobiol. B. 2015, 146, 34–43. [Google Scholar] [CrossRef] [PubMed]
  108. Jiang, X.; Lin, M.; Huang, J.; Mo, M.; Liu, H.; Jiang, Y.; Cai, X.; Leung, W.; Xu, C. Smart Responsive Nanoformulation for Targeted Delivery of Active Compounds from Traditional Chinese Medicine. Front. Chem. 2020, 8, 559159. [Google Scholar] [CrossRef] [PubMed]
  109. Law, S.; Leung, A.W.; Xu, C. Could nanotechnology assist traditional Chinese medicine (TCM) in photodynamic therapy (PDT) against SARS-CoV-2? Photodiagnosis Photodyn. Ther. 2021, 36, 102543. [Google Scholar] [CrossRef] [PubMed]
  110. Tang, W.; Xu, H.; Kopelman, R.; Philbert, M.A. Photodynamic characterization and in vitro application of methylene blue-containing nanoparticle platforms. Photochem. Photobiol. 2005, 81, 242–249. [Google Scholar]
  111. Wang, S.; Ha, Y.; Huang, X.; Chin, B.; Sim, W.; Chen, R. A New Strategy for Intestinal Drug Delivery via pH-Responsive and Membrane-Active Nanogels. ACS Appl. Mater. Interfaces. 2018, 10, 36622–36627. [Google Scholar] [CrossRef]
  112. Kabanov, A.V.; Vinogradov, S.V. Nanogels as pharmaceutical carriers: Finite networks of infinite capabilities. Angew. Chem. Int. Edit. 2009, 48, 5418–5429. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Download PDF
HIV-1 Transcription Inhibition Using Small RNA-Binding Molecules
Previous
Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses
Next